Inactive Instrument

Official Publications Organovo Holdings Inc Nyse

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 15	Organovo's fatty liver disease drug meets main goal in mid-stage study	RE
Apr. 15	Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	CI

No official publication found